The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML: long-term follow-up
Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses long-term findings from a Phase II trial of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML). Dr Short highlights encouraging long-term efficacy and safety outcomes. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
